...
首页> 外文期刊>Obstetrics and Gynecology: Journal of the American College of Obstetricians and Gynecologists >Titrated oral compared with vaginal misoprostol for labor induction: a randomized controlled trial.
【24h】

Titrated oral compared with vaginal misoprostol for labor induction: a randomized controlled trial.

机译:滴定口服液与阴道米索前列醇相比可引产:一项随机对照试验。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: To compare the efficacy and safety of titrated oral misoprostol and vaginal misoprostol for labor induction. METHODS: Women between 34 and 42 weeks of gestation with an unfavorable cervix (Bishop score less than or equal to 6) and an indication for labor induction were randomLy assigned to receive titrated oral or vaginal misoprostol. The titrated oral misoprostol group received a basal unit of 20 mL misoprostol solution (1 mcg/mL) every 1 hour for four doses and then were titrated against individual uterine response. The vaginal group received 25 mcg every 4 hours until attaining a more favorable cervix. Vaginal delivery within 12 hours was the primary outcome. The data were analyzed by intention-to-treat. RESULTS: Titrated oral misoprostol was given to 101 (48.8%) women and vaginal misoprostol to 106 (51.2%) women. Completed vaginal delivery occurred within 12 hours in 75 (74.3%) women in the titrated oral group and 27 (25.5%) women in the vaginal group (relative risk [RR] 8.44, 95% confidence interval [CI] 4.52-15.76). The incidence of hyperstimulation was 0.0% in the titrated oral group compared with 11.3% in the vaginal group (RR 0.08, 95% CI 0.01-0.61). Although more women experienced nausea (10.9%) in the titrated oral group (RR 27.07, 95% CI 1.57-465.70), fewer infants had Apgar scores of less than 7 at 1 minute in the titrated oral group than in the vaginal group (RR 0.10, 95% CI 0.01-0.76). CONCLUSION: Titrated oral misoprostol is associated with a lower incidence of uterine hyperstimulation and a lower cesarean delivery rate than vaginal misoprostol for labor induction in patients with unfavorable cervix. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00529295 LEVEL OF EVIDENCE: I.
机译:目的:比较滴定的口服米索前列醇和阴道米索前列醇引产的有效性和安全性。方法:妊娠34至42周且宫颈不良(Bishop评分小于或等于6)且有引产指征的妇女被随机分配接受滴定的口服或阴道米索前列醇治疗。滴定的口服米索前列醇组每1小时接受一次20毫升米索前列醇溶液的基础单位(1 mcg / mL),共四剂,然后针对个体子宫反应进行滴定。阴道组每4小时接受25 mcg的剂量,直到子宫颈变得更好为止。主要结果是在12小时内阴道分娩。通过意向治疗分析数据。结果:经滴定的口服米索前列醇给予101名(48.8%)妇女,经阴道的米索前列醇给予106名(51.2%)妇女。滴定口服组中有75名(74.3%)妇女和阴道组中有27名(25.5%)妇女在12小时内完成了阴道分娩(相对危险度[RR] 8.44,95%置信区间[CI] 4.52-15.76)。滴定口服液组过度刺激的发生率为0.0%,阴道组为11.3%(RR 0.08,95%CI 0.01-0.61)。尽管滴定口服液组中有更多的女性感到恶心(10.9%)(RR 27.07,95%CI 1.57-465.70),但是滴定口服液组中1分钟内Apgar得分低于7的婴儿少于阴道组(RR) 0.10,95%CI 0.01-0.76)。结论:口服米索前列醇滴定与宫颈米索前列醇引产相比,阴道过度刺激的发生率较低,剖宫产率较低。临床试验注册:ClinicalTrials.gov,www.clinicaltrials.gov,NCT00529295证据级别:I.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号